Charles Schwab’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Charles Schwab’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-225,435	Closed	-$7.62M	–	3598
2021 Q2	$7.62M	Buy	225,435 +15,455	+7%	+$394K	﹤0.01%	2144
2021 Q1	$4.91M	Buy	209,980 +6,019	+3%	+$182K	﹤0.01%	2313
2020 Q4	$5.88M	Buy	203,961 +1,172	+0.6%	+$29.5K	﹤0.01%	2141
2020 Q3	$4.11M	Buy	202,789 +137,780	+212%	+$3.36M	﹤0.01%	2171
2020 Q2	$1.95M	Buy	65,009 +18,432	+40%	+$664K	﹤0.01%	2439
2020 Q1	$1.46M	Buy	46,577 +7,663	+20%	+$266K	﹤0.01%	2392
2019 Q4	$1.83M	Buy	38,914 +6,602	+20%	+$191K	﹤0.01%	2445
2019 Q3	$209K	Hold	32,312	–	–	﹤0.01%	3036
2019 Q2	$397K	Hold	32,312	–	–	﹤0.01%	2918
2019 Q1	$438K	Buy	+32,312	New	+$290K	﹤0.01%	2808

Charles Schwab's CNST Position: Q3 2021 in Review

Charles Schwab sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 225,435 shares — an estimated $7.62M sold.

Charles Schwab first reported a position in CNST in Q1 2019 and held it in 10 quarters. The position peaked at $7.62M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

Charles Schwab reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 225,435 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $7.62M.
Charles Schwab first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2019 and held it in 10 quarters.
Charles Schwab's Constellation Pharmaceuticals, Inc. position peaked at $7.62M in Q2 2021.
0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.